Logo

trametinib

Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma

FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.

Johns Hopkins Team Develops Microfluidic Assay to Predict Risk of Breast Cancer Metastasis
Premium

The assay examine phenotypic behaviors of isolated cancer cells from biopsies at initial diagnosis.

Breaking News
The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.